Rebecca Uelmen

Rebecca Uelmen, PhD

Program Director, Valve Science Center

Rebecca Uelmen, PhD serves as Program Director of the Valve Science Center at the Minneapolis Heart Institute Foundation. In this role, she facilitates a multidisciplinary staff and physician team to advance research and education in valvular heart disease.

Dr. Uelmen brings nearly two decades of experience in cardiac research to MHIF, beginning her career as an academic researcher specializing in cardiac arrhythmias. During her seven-year tenure at Medtronic in the Structural Heart division, she led Medical Affairs and Scientific Communications teams focused on transcatheter and surgical heart valves. She is driven by a passion for utilizing evidence to advance treatment options and improve the lives of patients.

Dr. Uelmen holds a Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and a Bachelor Degree in Biology from St. Catherine University.

Back to Valve Team

Rebecca Uelmen
Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute FoundationĀ® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.